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Low level incorporation of the viral glycoprotein (Env) into human immunodeficiency virus (HIV) particles is a major drawback for vaccine
strategies against HIV/AIDS in which HIV particles are used as immunogen. Within this study, we have examined two strategies aimed at
achieving higher levels of Env incorporation into non-infectious pseudovirions (PVs). First, we have generated chimeric HIV/SIV Env proteins
containing the truncated C-terminal tail region of simian immunodeficiency virus (SIV)mac239-Env767stop, which mediates strongly increased
incorporation of SIV-Env into SIV particles. In a second strategy, we have employed a truncated HIV-Env protein (Env-Tr752N750K) which we
have previously demonstrated to be incorporated into HIV virions, generated in infected T-cells, to a higher level than that of Wt-HIV-Env.
Although the chimeric HIV/SIV Env proteins were expressed at the cell surface and induced increased levels of cell–cell fusion in comparison to
Wt-HIV-Env, they did not exhibit increased incorporation into either HIV-PVs or SIV-PVs. Only Env-Tr752N750K exhibited significantly higher
(threefold) levels of incorporation into HIV-PVs, an improvement, which, although not dramatic, is worthwhile for the large-scale preparation of
non-infectious PVs for vaccine studies aimed at inducing Env humoral responses.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV glycoprotein incorporation; SIV-Env truncation; HIV-Env truncation; PseudovirionIntroduction
The surface glycoproteins (Env) of membrane viruses are
responsible for mediating fusion between the viral and host cell
membranes and thus viral uptake into the target cell. The HIV-
Env proteins are the target proteins against which neutralising
antibodies from infected individuals are directed. Thus, vaccine
strategies against HIV/AIDS, which aim at inducing humoral
immune responses, employ and evaluate numerous types of
potential Env immunogen (for reviews, see Burton et al., 2004;
Pantophlet and Burton, 2006). These include monomeric and
oligomeric versions of wild-type or manipulated Env proteins or
peptides. Additionally, vaccines consisting of inactivated virus
particles or non-infectious pseudovirions (PVs), with incorpo-⁎ Corresponding author. Fax: +49 6221 424932.
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doi:10.1016/j.virol.2006.11.029rated Env proteins, have been analysed. In these latter cases, the
HIV Env proteins are membrane anchored and in a native
trimeric functional conformation, features which could be of
advantage for the induction of a neutralising antibody response.
However, the level of incorporation of Wt-Env into virions is
inherently low, a fact which is obviously counter-productive in
the situation in which Env epitopes are being targeted.
Quantitation of Env content in HIV particles by biochemical
methods (Chertova et al., 2002), by direct visualisation of viral
spikes by electron tomography (Zhu et al., 2003) or, more
recently, by cryoelectron microscopy tomography (Zhu et al.,
2006) point to there being an average of only 7–14 spikes per
HIV particle.
The nature of the processes, which govern the level and the
selectivity of glycoprotein incorporation into released HIV
particles, are still not completely clear. Of relevance in this
respect is the fact that, in contrast to the glycoproteins of other
membrane viruses, lentiviral glycoproteins contain very long
Fig. 1. Schematic representation of the modified HIV-Env and chimeric HIV-
SIV-Env constructs. The pseudovirion expression plasmid pHIV-Wt is shown at
the top and the respective Env proteins below. HIV sequences are depicted as
open bars and SIV-Env sequences by filled-in bars. The aa numbering of the
respective Env protein domains is given whereby the SIV Env aa are in
underlined italics. TMD=membrane anchor domain. The star shows the
position of the N750K mutation.
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acids (aa)). In the case of HIV-1, the presence of a full-length
151 aa long Env-CT region is essential for productive infection
in vivo and in most, but not all, T-cell lines in vitro. Several lines
of evidence point to there being an interaction between the HIV
matrix protein (MA) and the Env-CT region and to this being
required for the incorporation of full-length HIV-Env into HIV
virions (Cosson, 1996; Freed and Martin, 1995; Freed and
Martin, 1996; Mammano et al., 1995; Wyma et al., 2000).
Recently, the TIP47 protein has been shown to be an essential
cellular cofactor mediating association between MA and the
Env-CT (Lopez-Verges et al., 2006). On the other hand, it is
clear that membrane protein incorporation into HIV particles is
not restricted to the homologous full-length glycoprotein. Thus,
many host cellular proteins (e.g., adhesion molecules which
also modulate viral infectivity) (Bastiani et al., 1997) as well as
many heterologous viral glycoproteins (which mediate viral
pseudotyping) can be incorporated into retroviral, including
HIV, particles. Furthermore, HIV-Env, lacking the Env-CT
region, can also be incorporated into HIV particles and
additionally can pseudotype murine leukaemia virus (MuLV)
vector particles (Mammano et al., 1997; Schnierle et al., 1997;
Wilk et al., 1992). The factors governing this type of
“unspecific” incorporation are not completely understood but
may require only that the respective glycoprotein colocalises to
the cellular site of HIV particle assembly and release.
The Env protein of simian immunodeficiency virus (SIV)
also contains a long CT region and similar to the situation with
HIV, wild-type SIV-Env is also only poorly incorporated into
SIV particles (Chertova et al., 2002; Zhu et al., 2003; Zhu et al.,
2006). However, replication of SIV in human cells leads to
selection of Env proteins which are C-terminally truncated and
these C-terminally truncated SIV-Env proteins frequently
exhibit increased incorporation levels (Zingler and Littman,
1993). In a study comparing the incorporation levels of SIV Env
proteins truncated at different positions within the cytoplasmic
C-terminus, it could be demonstrated that truncated SIV Env,
consisting of 766 aa (SIVmac239-Env767stop), was incorporat-
ed into SIV particles at levels which were up to 50-fold higher
than that of WT-SIV-Env (Yuste et al., 2004). Thus, since the
SIVmac239-Env767stop-CT region is compatible with high
SIV-Env incorporation, or may actually positively influence it,
in a first strategy we have generated chimeric HIV-SIV-Env
proteins containing this region. We have analysed the
expression and functionalities of the respective proteins and
their incorporation levels into both HIV and SIV pseudovirion
particles.
In the case of HIV-Env, truncations within the CT at
positions equivalent to those, which in SIV-Env result in
increased incorporation into SIV particles, did not lead to a
similar strong increase in incorporation of HIV-Env into HIV
particles. We have, however, recently described a mutant HIV,
pNL-Tr752N750K, encoding Env with a specific truncation
within the CT, which exhibited clearly increased incorporation
into HIV particles produced by infection of T-cells (Holtkotte et
al., 2006). Thus, in a second strategy, we have included this
mutant Env protein in this study and have analysed ifincorporation into non-infectious HIV-PVs, produced by
transfection of subviral expression plasmids, is also increased.
Results and discussion
Expression and functionality of wild-type and modified Env
proteins
The subviral construct pHIV-Wt, which expresses non-
infectious wild-type HIV pseudovirions (PVs), and derivatives
thereof encoding truncated and chimeric HIV/SIV env genes
are schematically depicted in Fig. 1. pHIV-Env-Tr752N750K
encodes an HIV-Env protein with a stop codon at position 753
and an additional aa change at position 750 (N750K). In the
context of virions produced from infected T-cells, these changes
have been shown to lead to increased Env incorporation
(Holtkotte et al., 2006). pHIV-Env-HS767stop encodes the
ectodomain and membrane anchor domain (TMD) of HIV-Env
followed by a truncated version (E767stop) of the SIV Env-CT.
pHIV-Env-SS767stop is identical to pHIV-Env-HS767stop but
encodes the SIV Env-TMD. In the SIV proviral context,
truncated SIV-Env (E767stop) is incorporated into SIV particles
at very significantly increased levels (Yuste et al., 2004).
As established by ELISA for HIV-CA, the amounts of PVs,
released into the culture supernatants of 293T cells transfected
with pHIV-Wt and derivatives, were equivalent for all the
constructs (not shown). This shows that rev gene expression has
not been affected by insertion of the SIV-env sequences a few
nucleotides upstream of the rev splice acceptor site. Env protein
expression was confirmed by Western blot analysis (see Fig.
3A) and the functionalities of the expressed Env proteins
analysed in a semi-quantitative cell–cell fusion assay (Fig. 2).
In this assay, 293T cells transfected with the respective plasmids
were cocultivated with 1G5 cells, which carry a fire-fly
luciferase reporter gene under control of the HIV-LTR promoter.
293T cells transfected with pHIV-Env-CD4−, encoding for
Fig. 3. Expression of wild-type and modified Env proteins and incorporation
into HIV particles. Western blot analysis of (A) equalised amounts (with respect
to amounts of released HIV-CA in the culture supernatant (CA-ELISA)) of
lysates of 293T cells transfected with pHIV-Wt and the respective derivatives as
indicated and (B) of equalised amounts of concentrated PVs (equivalent to
100 ng HIV-CA as determined by CA-ELISA) as well as of standard amounts of
recombinant gp120 as indicated. The top parts of the filters have been probed
with rabbit gp120 antibodies, the middle parts with gp41 Mab Chessie 8 and the
bottom parts with p24 Mab. In panel B, middle portion, the arrow marks the
position of Wt gp41 and the additional bands in all samples are background
bands in this blot. Note that the gp41 epitope in the Env-CT region, recognised
by the gp41 Mab Chessie 8, is not present in the two chimeric Env proteins with
the SIV-CT. The positions of the respective viral proteins are shown on the right.
Fig. 2. Cell–cell fusion capacity of the Wt and modified Env proteins. 293T
cells, transfected with pHIV derivatives, expressing the respective Env proteins
as shown, were cocultured from 48 to 52 hpt with 1G5 T-cells, which carry an
integrated LTR-luciferase construct. Subsequently, the cocultured cells were
lysed, luciferase activities (given in relative light units (RLU)) were measured
and, if necessary, these were normalised to the respective viral gene expression
levels in the infected cells (quantitated by CA-ELISA in the culture
supernatants). The luciferase values for pHIV-Wt were set at 1.0 and the
relative values (shown above each column) for the other derivatives calculated
(fold fusogenicity in this cell–cell fusion assay). The results from one of two
experiments with similar results are given.
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binding site, were employed as negative control for possible
transactivation induced by secreted Tat or by spontaneous
fusion. In this case, the luciferase value measured, reflecting the
extent of cell–cell fusion occurring, was in the range of the
background. In comparison to Wt-Env, chimeric Env-SS767stop
induced about twofold and Env-Tr752N750K and chimeric Env-
HS767stop each about 10-fold more cell–cell fusion. Increased
fusion capacities of C-terminally truncated HIV-Env (Wilk et
al., 1992), SIV-Env proteins (Spies and Compans, 1994) and,
specifically, of HIV-Env-Tr752N750K expressed in infected T-
cells (Holtkotte et al., 2006) have previously been described.
These results show that the modified proteins are functional and
have been transported to the cell surface.
Incorporation of wild-type and modified Env proteins into HIV
and SIV particles
Fig. 3 shows Western blot analysis of lysates of 293T cells
transfected with the respective pHIV constructs and of
pseudovirion particles concentrated from the culture super-
natants. As can be seen from the intensities of the gp160 and
truncated gp140 protein bands in the cell lysates, the expression
levels of the different glycoproteins were similar in all cases.
The amounts of gp120 and gp41 species incorporated into
released PVs were, however, different. The intensities of the
gp120 and p24 bands were quantitated by densitometry and the
relative gp120 incorporation (corrected for slight differences in
the amounts of CA loaded) calculated. The data from the blot in
Fig. 3B and from blots from several further experiments
revealed that incorporation of Env-Tr752N750K was on averagethreefold higher than that of Wt-Env. It is important to
reemphasise here that Env-Tr752N750K is present in a function-
ally authentic conformation in the viral membrane since
infectious pNL-Tr752N750K virions mediate spreading infec-
tions in T-cells (Holtkotte et al., 2006) and exhibit wild-type
levels of infectivity in a single-round assay (data not shown).
The incorporation levels of the two chimeric HIV-SIV-Envs
were not increased but were rather only similar (Env-HS767stop)
or somewhat reduced (about 0.5-fold, Env-SS767stop) in
comparison to Wt-HIV-Env. In Fig. 3B, PVs containing
100 ng CA have been analysed. Thus, by densitometric
comparison to the standard amounts of gp120 on the same
blot, we have calculated that the amount of incorporated gp120
in pHIV-Env-Tr752N750K-PVs was about 100 ng gp120 per μg
CA. The fact that the incorporation levels of Env-HS767stop and
of Env-SS767stop into HIV-PVs were not increased means that
the truncated SIV-CT767stop domain, which in the SIV-Env/SIV-
PV context leads to increased SIV-Env incorporation, does not
do so in the context of HIV-Env/HIV-PV. This is despite the fact
Fig. 4. Incorporation of wild-type and modified Env proteins into SIV particles.
The respective HIV-PVs and SIV-PVs, equalised with respect to CA content
(estimated to be 100 ng p24 or p27), have been analysed as indicated. The top
portion of the blot has been probed with gp120 antibodies, the middle portion
with gp41 Mab Chessie 8 and the bottom portion with HIV p24 Mab which,
however, cross-reacts with SIV-p27. The positions of the respective viral
proteins are shown on the right. Note that the gp41 epitope recognised by gp41
Chessie 8 Mab is no longer present on the chimeric HIV-SIV-Env proteins. The
individual lanes, here separated by a dotted line, are derived from non-adjacent
lanes of the same exposure of the same blot.
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about 10-fold increased cell–cell fusion capacity in comparison
to Wt-Env, a property which, at least in part, is likely to be due
to increased expression at the cell surface.
In addition to cell surface expression levels, other factors can
also influence Env incorporation levels. These can include
localisation of the respective Env protein to specific subdo-
mains, e.g., lipid rafts, of the plasma membrane where PV
budding occurs (Ono and Freed, 2005). Additionally, there may
be a requirement for compatibility between the CT region of an
incorporated glycoprotein and the internal structural proteins of
the respective PVs. Thus, since the truncated SIV-CT767stop
domain has been derived from SIV-Env, we considered the
possibility that the chimeric Env-HS767stop and Env-SS767stop
proteins would perhaps be more efficiently incorporated into
SIV pseudovirions.
First we wanted to confirm if as reported (Yuste et al., 2004)
SIV-Env767stop is incorporated into SIV particles at higher
levels than that of Wt-SIV-Env. We generated particles either
employing SIV proviral plasmids or by cotransfection of
expression vectors for Wt-SIV-Env or SIV-Env767stop
(pSIVΔgp derivatives; Yuste et al., 2004) with pcDNA3.1-
SIV-syn-Gag-Pol, which is an expression vector for SIV-PVs. In
both cases, the incorporation levels of SIV-Env767stop into SIV
particles, concentrated from the culture supernatants of
transfected 293T cells, were higher than those of Wt-SIV-Env.
However, in our hands, the levels of increase were not 50-fold
as described previously (Yuste et al., 2004) but were only in the
range of 4- to 5-fold (data not shown). We then investigated if
the levels of incorporation of the chimeric Env-HS767stop and
Env-SS767stop proteins into SIV-PVs were higher than into
HIV-PVs and if they were possibly superior to the level of
incorporation of Env-Tr752N750K into HIV-PVs. SIV-PVs were
generated by cotransfection of phCMV-Env-HS767stop or
phCMV-Env-SS767stop, which are CMV-promoter driven Env
expression vectors for the respective chimeric proteins, with
pcDNA3.1-SIV-syn-Gag-Pol and pCMVrev. Although both rev
gene exons are intact in the phCMV-Env context, we observed
that it was necessary to additionally cotransfect a Rev
expression plasmid in order to achieve high Env expression
levels. This is likely due to suppression of translational
initiation at the downstream rev AUG in a bicistronic mRNA
in which the tat AUG, with its optimal Kozak sequence, is
upstream (Schwartz et al., 1992). HIV-PVs were generated from
pHIV-Wt and pHIV-Env-Tr752N750K. The amounts of HIV-CA
and SIV-CA in the respective concentrated PV preparations
were estimated by gel electrophoresis and Coomassie blue
staining in comparison to standard amounts of purified HIV-
CA. Fig. 4 shows Western blot analysis of the different PVs,
equalised with respect to CA content. Incorporation of Env-
HS767stop into the SIV PVs has clearly occurred whereas Env-
SS767stop was hardly incorporated at all. Densitometric
quantitation of band intensities revealed that the level of
incorporation of Env-HS767stop into the SIV-PVs was about
half of that of Wt-Env into HIV particles and was clearly less
than the level of incorporation of Env-Tr752N750K into HIV
particles. This means that the SIV-CT-767stop region is notsufficient to mediate increased incorporation of the chimeric
Envs into SIV-PVs.
Comparison of Env incorporation into PVs and into infectious
virions generated in different cell lines
It has been reported by others that the level of Env
incorporation into HIV produced in 293T cells was markedly
inferior to that achieved when the same virions were generated
in PBMCs (Louder et al., 2005). To follow up on this, we have
analysed Env incorporation levels into non-infectious PVs and
into infectious virions, these latter produced either in transfected
293T cells or in infected T-cells (Fig. 5). Fig. 5A shows analysis
of particles produced in transfected 293T cells. Densitometric
quantitation of band intensities showed that Env incorporation
into provirally expressed infectious pNL-Wt virions was about
threefold higher than into the equivalent, but subvirally
expressed, Wt-PVs. Thus, when both are produced in
transfected 293T cells, the incorporation level of Env-
Tr752N750K into PVs is approximately similar to that of Wt-
Env into infectious virions. The reason for this difference in Env
incorporation levels into virions expressed from proviral or
subviral plasmids has not been investigated further. In Fig. 5B,
pNL-Wt virions produced in different cell lines have been
analysed. Quantitation of band intensities revealed that Env
incorporation levels were equivalent when pNL-Wt virions
were generated in transfected 293T cells or in infected MT-4
cells but were about twofold higher when the same virions were
produced in infected H9 T-cells or in PBMCs. This means that
Fig. 5. Env incorporation into virus particles generated in different cell lines.
Equalised amounts of HIV-PVs or infectious Wt-pNL4-3 virions produced in
transfected 293T cells or in infected T-cell lines or in PBMCs were analysed as
indicated. (A) Samples generated in transfected 293T cells, neg.=centrifuged
materials from the supernatants of 293T cells transfected with an expression
vector for Wt-Env alone. (B) pNL-Wt virions generated in transfected 293Tcells
(the same sample as in panel A) or in MT-4 cells, H9 cells or PBMCs as shown.
The top portion of the blots have been probed with gp120 serum and the bottom
portion with p24 Mab. The positions of the respective viral proteins are shown.
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approximately equivalent to that observed for Wt-Env into
infectious virions generated in 293T cells (seen in Fig. 5A), it is
only marginally (twofold) lower than the levels incorporated
into virions produced in PBMCs, in which Env incorporation
into particles is presumably optimal.
The use of non-infectious PVs, rather than of inactivated
virions for vaccine strategies has clear advantages with respect
to safety and ease of manipulation. Large-scale preparation of
virus or PV particles for vaccine testing can only be practically
achieved by transient or stable transfection of suitable cell lines.
In this scenario, the threefold increase in functional Env
incorporation into PVs, which has been achieved employing
Env-Tr752N750K, represents a significant improvement for the
generation of PV-based vaccines.
Materials and methods
Constructs
In this paper HIV nucleotide numbering is derived from
proviral pNL4-3 (Adachi et al., 1986), HIV-Env aa numbering
is from BH10 Env (Hahn et al., 1984) and SIV nucleotide and aanumberings are from SIVmac239 (Kestler et al., 1990). PC-
HIV, referred to here as pHIV-Wt, is an expression vector for the
entire HIV genome except nef under control of the CMV
promoter (Lampe et al., in press). PhCMV-Env is an HIV-Env
expression construct generated by insertion of the SalI–XhoI
fragment from pNL4-3 (HIV nucleotides 5785–8887, contain-
ing the tat, rev, vpu and env genes) into phCMV (Genlantis,
USA) linearised with BamHI. Constructs encoding chimeric
HIV-SIV Env proteins were generated using standard PCR
technology. BsaBI–XhoI fragments (HIV nucleotides 7545–
8887) of these generated sequences as well as from pNL-
Tr752N750K (Holtkotte et al., 2006) were employed to replace
the same fragments in pHIV-Wt or in phCMV-Env. Env-
Tr752N750K is an HIV-Env protein truncated after aa 752 and
with an additional aa change at position 750 (N750K). Env-
HS767stop and Env-SS767stop both contain the entire ectodo-
main from HIV-Env (aa 1–683). In Env-HS767stop, the
membrane anchor domain (TMD) has been derived from HIV-
Env (aa 684-705) whereas in Env-SS767stop it has been derived
from SIVmac239-Env (aa 693–714). In both cases, the
cytoplasmic tail (CT) region is a truncated form of the
SIVmac239-Env CT (aa 715–766, stop codon at SIV Env
codon 767). The SIV Env-CT sequences replace HIV Env aa
706–713, i.e., they have been inserted 5′ to HIV nucleotide
8353, i.e., upstream of rev exon 2. Nucleotides 8353 to the XhoI
site at position 8887 are derived from HIV-1. The authenticity of
the introduced changes was confirmed by sequencing. For
technical reasons, in Env-SS767stop there are two conservative
aa changes (I675L and L679I) in the HIV ectodomain just
upstream of the TMD. The respective plasmids carry the prefix
pHIV (derivatives of pHIV-Wt encoding for all HIV gene
products except Nef) or phCMV (Env expression constructs).
pHIV-Env-CD4(−) is a derivative of pHIV-Wt with a deletion of
12 Env aa in gp120 abrogating binding to CD4 (Lasky et al.,
1986). pCMVrev is an expression vector for HIV-Rev.
pcDNA3.1-SIV-syn-Gag-Pol is an expression vector for
codon-optimised versions of the SIVmac239 gag and pol
genes and was kindly provided by R. Wagner, University of
Regensburg, Germany. pMD.G is an expression vector for the
viral glycoprotein G of vesicular stomatitis virus (VSV-G)
(Naldini et al., 1996).
Cell culture, transfections and infections
293T cells were cultivated in DMEMmedium, 10% fetal calf
serum (FCS) and MT-4 and H9 T-cell lines, as well as reporter
Jurkat 1G5 cells, in RPM-I medium, 10% FCS. Freshly
prepared peripheral blood mononuclear cells (PBMCs) were
maintained in RPM-I medium, 10% FCS and activated with
1 μg/ml phytohemagglutinin (PHA), 25 U/ml interleukin-2 (IL-
2) for 2 days prior to infection with HIV. Transfections of 293T
cells were performed using standard calcium phosphate
transfection procedures. Infections of MT-4 cells, H9 cells or
PBMCs were initiated with VSV-G pseudotyped virions
released into the medium of 293T cells cotransfected with
pNL4-3 and pMD.G. After 5 h, input virus was removed, the
cells were washed three times with medium and cultivated
470 G. Devitt et al. / Virology 361 (2007) 465–471further in the original volume of RPM-I, 10% FCS containing
5 μg/ml anti-CD4 Mab (Pharmingen, BD Biosciences) or
1 μg/ml AMD3100 (kindly supplied by D. Schols and E.
deClerq, University of Leuven, Belgium), which block binding
of gp120 to CD4 or CXCR-4, respectively, and prevent Env-
mediated cytotoxicity. This reduces the risk of contamination
of concentrated virions with membranous debris from lysed
cells.
Analysis of proteins in cells and in released pseudovirions and
virions
Culture supernatants of transfected 293T cells or infected T-
cells were filtered through a 0.45-μm filter and released virus
particles concentrated by centrifugation at 200,000×g for 3 h
through a cushion of 20% sucrose. Transfected cells and
concentrated PVs or virions were lysed in 1% Triton X-100 in
phosphate-buffered saline (PBS). The amounts of PVs or
virions in culture supernatants or after concentration were
quantitated by p24 antigen capture ELISA (NCI-Frederick
Cancer Research and Development Center, Frederick, USA). In
order to estimate the amounts of SIV CA (p27) in SIV
pseudovirions concentrated from transfected 293T cells,
aliquots of the respective samples were subjected to gel
electrophoresis and staining with Coomassie blue in compar-
ison to standard amounts of HIV-CA. Aliquots of cell or viral
lysates, adjusted to contain equal levels of HIV-CA or SIV-CA,
were subjected to Western blot analysis employing rabbit gp120
antibodies, anti-gp41 Mab Chessie 8 (Abacioglu et al., 1994)
and anti-p24 Mab 183-H12-5C (Chesebro et al., 1992).
Reactive bands were visualised employing peroxidase-coupled
secondary antibodies and fluorography. Comparative densito-
metric quantitation of specific bands on different exposures of
the blots to film was carried out using the Image Quant TL
software from Amersham Biosciences.
Quantitation of cell–cell fusion
293T cells transfected with the respective pHIV plasmids
(in wells of a 6-well dish) were cocultivated from 48 to 52 hpt
with 1 ml confluent 1G5 cells, which are Jurkat T-cells
containing a stably integrated HIV-LTR fire-fly luciferase
construct (obtained from the AIDS Research and Reference
Reagent Program, NIH). We had previously established in a
control experiment that the 4-h time point of cocultivation is
in the linear phase of increase in luciferase expression,
induced by ongoing membrane fusion. At later time points,
this increases plateaus. During cocultivation, Env-mediated
syncytium formation between the two cell types results in
activation of LTR-driven luciferase expression by Tat protein,
synthesised in the transfected 293T cells. The cocultured cells
were then lysed and luciferase activities, reflecting the extent
of membrane fusion induced by the respective Envs, measured
using standard procedures. In order to normalise for possible
differences in transfection efficiencies, the amounts of released
VLPs in the respective culture supernatants at 48 hpt were
determined by CA-ELISA (these were generally in the samerange) and the measured luciferase values were adjusted
accordingly.
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